With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 29, 2017. Prelim results of the Phase III ADJUVANT trial were published this month in JCO showing a benefit with the use of post-opgefitinib (an EGFR-TKI) in EGFR-mutant non-small cell lung cancer (NSCLC) patients with completely-resected pN1-2 disease. 222 patients were randomized post-op to received gefitinib (daily pill) x 24 months versus vinorelbine/cisplatin (IV q3 weeks) x 4 cycles. With a median follow-up of 36 months, median disease-free survival was 29 months with gefitinib versus 18 with chemo (p=0.005). This is a big win for a targeted EGFR agent following big losses in 2013 and 2015, likely due to better molecular selection of patients. And if you think a pill for solid tumors is unlikely to star in any upcoming DEFINITIVE trial, breast cancer has something to say about that.